Linear DNA STINKS!STRONG SELL RECOMMENDATION - 600 Reasons to Sell this Dumpster Stock
241. It is imperative that you understand one important thing. APDN is an experimental company.
242. The research APDN is currently doing is completely experimental. Clinical tests have not been performed! Proof of concept for successful commercialization has not been completed. The risks with APDN are enormous. Do not underestimate the extreme risks with APDN!!
243. It will take many years to commercialize any potential product. And that’s a big if!
244. Unfortunately, CEO Hayward refuses to disclose these critical facts.
245. There’s a huge technology war going on today involving DNA and RNA replication.
246. How can APDN compete against multibillion dollar companies like Moderna?
247. Moderna employs hundreds of the best scientists in the world. That’s a fact!
248. Moderna spends billions of dollars on R & D. That’s a fact!
249. On the other hand, APDN spends most of its money on insider compensation, leaving very little for R & D. That’s a fact!
250. I just can’t imagine how APDN can ever be successful. It’s nearly impossible! That’s a fact!
STRONG SELL RECOMMENDATION - 600 Reasons to Sell this Dumpster Stock
251. I know someone who works in Venture Capital and asked him about APDN. He told me that his company does its due diligence to an extreme.
252. He looked at APDN and told me no VC firm will touch this company. It has many problems.
253. It's always short on funding. Reverse stock splits are often a death knell for a company. And the company simply is not focused.
254. He told me a story about vitamin water. He said a sports player paid $1 million in seed money and a few years later Coke bought him out for $100 million. VC firms work in much the same way.
255. He explained that the company making vitamin water was extremely focused. They did one thing and they did it very well.
256. Also, it was very simple and everyone knows about vitamins and water. So there are no surprises here.
257. On the other hand, APDN is not focused on any one product. The products they are working on are all new technologies without a long-track record and you can bet there will be some surprises and setbacks.
258. He also said that investing in this company carries way too much risk.
259. It should have been a private company, but the insiders wanted to take APDN public so they could make more money and could more easily liquidate their holdings.
260. He also added, "Don't even try to trade this stock, it is way too dangerous!"